TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.

Mrinal M Gounder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.